TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03704766

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum C-reactive Protein (CRP)
Description: A blood test performed at the hospital.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum C-reactive Protein (CRP)
Description: A blood test performed at the hospital.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum D-dimer
Description: A blood test performed at the hospital.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum D-dimer
Description: A blood test performed at the hospital.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum Procalcitonin
Description: A blood test performed at the hospital.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum Procalcitonin
Description: A blood test performed at the hospital.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Cultures
Description: Blood will be cultured at the hospital to see if any organisms grow.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood Cultures
Description: Blood will be cultured at the hospital to see if any organisms grow.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optional blood testing per standard of care (ASO, anti-strep, ANA, anti-DS-DNA, HLA-B27, RF, Lyme and other inflammatory/ rheumatologic markers )
Description: In patients with suspected inflammation/infection, there are other blood tests which may be standard of care and used for diagnosis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Optional blood testing per standard of care (ASO, anti-strep, ANA, anti-DS-DNA, HLA-B27, RF, Lyme and other inflammatory/ rheumatologic markers )
Description: In patients with suspected inflammation/infection, there are other blood tests which may be standard of care and used for diagnosis.
Study: NCT00527566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: IV mepolizumab, 750 mg
Study: NCT00783926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
Description: 2 x 0.5 mL intramuscular injections 21 days apart (one of six different doses of hemagglutinin antigen without adjuvant)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
Description: 2 x 0.5 mL intramuscular injections 21 days apart (one of six different doses of hemagglutinin antigen without adjuvant)
Study: NCT00974324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostar and CHOP
Description: endostar, 7.5m g/m2, intravenous, Day 2-15, repeat every 3 weeks~CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone
Study: NCT01914094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehab
Study: NCT02800850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright Light

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Light
Study: NCT05616962

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Diosmiplex
Description: diosmin glycoside in combination with alkaline granules known as alka4-complex
Study: NCT02247427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy Device
Description: Cardiac Resynchronization Therapy Device pacing activity, on or off
Study: NCT02970500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate HCl 10Mg SR
Description: Methylphenidate HCl 10Mg SR (Phase 1) and Methylphenidate HCl 20Mg SR (Phase 2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Placebo
Study: NCT00931372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Solution for subcutaneous injection 100 µg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Solution for subcutaneous injection 100 µg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT03683069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone vs Amlodipine
Description: We posit that decreases in striatin activity/levels increases aldosterone secretion resulting in hypertension and salt sensitive blood pressure. Thus, our mechanistic clinical study will assess whether hypertensive striatin risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the striatin risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure with a secondary outcome of salt sensitive blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone vs Amlodipine
Description: We posit that decreases in striatin activity/levels increases aldosterone secretion resulting in hypertension and salt sensitive blood pressure. Thus, our mechanistic clinical study will assess whether hypertensive striatin risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the striatin risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure with a secondary outcome of salt sensitive blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
Study: NCT03321916

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 577-nm PASCAL laser
Description: The Topcon/Endpoint Management System™ is a cleared medical device commonly used in the treatment of ocular disorders.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 577-nm PASCAL laser
Description: The Topcon/Endpoint Management System™ is a cleared medical device commonly used in the treatment of ocular disorders.
Study: NCT04429516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: over-encapsulated Morphine Sulfate prolonged release 5mg tablet, twice daily for 14 days. Patients will then crossover after a 7 day wash out period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: capsule containing Microcrystalline Cellulose Ph. Eur, 5 mg twice daily
Study: NCT03889743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment during 3 days
Description: Dexamethasone 1,0 mg oral tablets. The exact daily dose of dexamethasone will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment during 3 days
Description: 1,0 mg oral tablets. The exact daily dose of lactose (instead of dexamethasone) will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
Study: NCT06402734

Intervention type: BEHAVIORAL
Intervention: Adherence to Gluten Free Diet
Description: Participants with a diagnosed celiac disease were following a gluten-free diet. Study observed the adherence to the gluten-free diet for 6 weeks.
Study: NCT01704170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kona Externally Focused Ultrasound Therapy
Study: NCT00302796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bioclavid
Description: 500 + 125 mg times 3 or 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bioclavid
Description: 500 + 125 mg times 3 or 6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01009931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12-O-tetradecanoylphorbol-13-acetate
Description: The initial dose of TPA will be 1 mg/week x 3 weeks (Day 1, 8, 15). Up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg PO qid will start 24h prior to TPA and continue for 24h after TPA x 3 weeks. Up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate
Description: Choline magnesium trisalicylate 1500 mg PO TID will begin 24h prior to TPA and continue for 24h post TPA x 3 weeks.~Up to 6 cycles.
Study: NCT02110641

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Counseling
Description: The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
Study: NCT04137042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Intraoperative fluid therapy is administrated by using 0.9% saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced crystalloid
Description: Intraoperative fluid therapy is administrated by using balanced crystalloid
Study: NCT02527668

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcifediol
Description: One capsule orally of Calcifediol (20 µg) per day with a meal for a duration of 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: One capsule orally of Cholecalciferol (3200 IU) per day with a meal for a duration of 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule orally of a Placebo capsule per day with a meal for a duration of 6 months
Study: NCT01219348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDO peptide vaccination
Description: Vaccination every second week
Study: NCT00479245

Intervention type: OTHER
Group type: OTHER
Intervention: Set of questionnaires (respondent)
Description: To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
Study: NCT04546581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
Description: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is derived from the plasma of individuals who recover and develop neutralizing antibodies. Participants will receive a single infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single infusion of the placebo (saline).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir will be given to participants in both groups as standard of care (SOC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir will be given to participants in both groups as standard of care (SOC).
Study: NCT02212756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M 1200mg and Metformin 1000mg
Description: Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M 1200mg and Metformin 1000mg
Description: Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000mg
Description: Metformin 500mg b.i.d. for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000mg
Description: Metformin 500mg b.i.d. for 7 days
Study: NCT02638584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: Rabeprazole 20mg 1tablets once a day(1 times / day), before breakfast
Study: NCT00719485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program
Description: Informing patients about their condition, treatment options, prioritization on the wait list, and post-operative care
Study: NCT04366843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chair massage
Description: Chair massage was performed useing only traditional methods of Swedish massage were used, consisting of stroking (smooth, continuous movements to relax and calm the sympathetic nervous system), kneading (consisting of wringing, squeezing muscles, compressing pressure points for the relaxation of soft tissues, i.e. muscles, tendons, fascia), stretching combined with swaying and passive movements of the upper limbs (to mobilize the joints of the upper limbs) and final stroking combined with slapping and shaking percussion, vibration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the exercise program
Description: The original set of exercises was developed based on the knowledge and clinical experience of the authors of the study and based on EBP (Evidence Based Practice). The program consisted of 14 strengthening and stretching exercises involving the muscles of the trunk and limbs whose main goal was to mobilize the joints and strengthen the weakened muscles and relax overloaded muscle groups.
Study: NCT02035202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT2go
Description: CBT administered using mobile intervention.
Study: NCT01702337

Intervention type: OTHER
Intervention: Prevalence-based model
Description: Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).

Intervention type: OTHER
Intervention: Prevalence-based model
Description: Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).
Study: NCT01928719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Content Cigarettes
Description: Cigarettes contain 11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg nicotine per cigarette

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Same Nicotine Content Cigarettes
Description: about 11.6 mg nicotine per cigarette
Study: NCT02648581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Ustekinumab
Description: Injections of ustekinumab at 90 mg at week 0, week 4 and week 16. Patients in treatment failure at week 24 will terminate the study. Responder patients at week 24 will receive additional 2 injections of ustekinumab at week 28 and week 40 with a final evaluation at week 52.
Study: NCT02043496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Cognitive-Affective Therapy
Description: Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-Guided Self Help
Description: CBT-Guided Self Help focuses on changing behavior patterns through the use of reading and homework assignments along with sessions with a therapist.
Study: NCT04654780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taxes
Description: a High in food tax will be applied to study changes in purchasing and consumption behavior of participants in this group. The tax will correspond to a 20% increase over the market price, that is, a tax that reaches the levels recommended by the WHO.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subsidies
Description: A subsidy will be applied to fruits and vegetables that means a reduction of 20% in their price, to study the changes in purchasing behavior and of the participants of said group.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Average or current food prices will apply. Based on the average of the values reported by three supermarkets
Study: NCT03939052

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Free amino acids intake
Description: Oral consumption of eight hourly experimental meals- -4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil -4 isotopically labeled experimental meals. The same protocol will be repeated with glycomacropeptide (GMP).
Study: NCT04326543

Intervention type: DIAGNOSTIC_TEST
Intervention: Swanson, Noolan and Phelham - IV edition (SNAP-IV); Conners' Parent Rating Scales (CPRS)
Description: * Ratings on the Swanson, Nolan and Pelham Evaluation Scale - IV (Bussing et al., 2008), were assessed during baseline visit for participants at the time of research assessment, to exclude the presence of ADHD symptoms in the healthy subjects. This scale is composed of 26 items for ADHD symptoms and ODD and was administered at baseline and at follow-up visit.~* Temperament assessment: we used the Mary Rothbart's Temperament Questionnaire, a caregivers' report measure designed to provide a detailed assessment of temperament.~* ADHD Rating scales: the Long Version of Conners' Parent Rating Scale (Conners et al., 1998) was used to quantify ADHD comorbidity symptoms, as ODD and Anxiety traits, in the children and adolescents with ADHD.~* Salivary cortisol: Sampling was performed during one ordinary weekday between 7 and 8 o'clock, within 60' after nocturnal awakening.
Study: NCT02035202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: A smartphone platform will be used to deliver the CBT2go behavioral intervention and the surveys in the EMA-only arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Description: A smartphone platform will be used to deliver the CBT2go behavioral intervention and the surveys in the EMA-only arm.
Study: NCT00894439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-489/Piperacillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin
Study: NCT00893412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
Description: 1 tablet of 50 mg Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
Description: 1 tablet of 50 mg Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hysterosalpingography (HSG)
Description: One HSG using a metal canula or balloon catheter, 30 minutes after tablet

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hysterosalpingography (HSG)
Description: One HSG using a metal canula or balloon catheter, 30 minutes after tablet

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterosalpingography (HSG)
Description: One HSG using a metal canula or balloon catheter, 30 minutes after tablet

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterosalpingography (HSG)
Description: One HSG using a metal canula or balloon catheter, 30 minutes after tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01055691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/Metformin
Description: Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/Metformin
Description: Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: dapagliflozin tablet 2.5 mg Oral Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: dapagliflozin tablet 2.5 mg Oral Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin IR tablet 850 mg Oral Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin IR tablet 850 mg Oral Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/Metformin
Description: Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/Metformin
Description: Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: dapagliflozin tablet 5 mg Oral Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: dapagliflozin tablet 5 mg Oral Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin IR tablet 1000 mg Oral Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin IR tablet 1000 mg Oral Single dose
Study: NCT02693145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-Retroviral Treatment and Access to Services (ARTAS)
Description: Anti-Retroviral Treatment and Access to Services (ARTAS) is an individual-level, multi-session, time-limited intervention with the goal of linking recently diagnosed persons with HIV to medical care soon after receiving their positive test result. ARTAS is based on the Strengths-based Case Management (SBCM) model, which is rooted in Social Cognitive Theory (particularly self-efficacy) and Humanistic Psychology. SBCM is a model that encourages the client to identify and use personal strengths; create goals for himself/herself; and establish an effective, working relationship with the Linkage Coordinator (LC).